Thalidomide 4'-ether-alkylC2-amine hydrochloride

Background Introduction

Thalidomide 4'-ether-alkylC2-amine hydrochloride is a synthetic small molecule designed as a versatile E3 ligase ligand-linker conjugate. It features a thalidomide core structure, renowned for its cereblon (CRBN) binding properties, linked via a 2-carbon (C2) alkyl chain terminated with an amine hydrochloride group. This optimized structure facilitates its integration into Proteolysis Targeting Chimeras (PROTACs) for targeted protein degradation strategies. As an advanced building block, this molecule enables streamlined assembly of functional PROTACs to selectively manipulate protein homeostasis within cells.

Mechanism

This compound operates by harnessing thalidomide’s ability to bind to the CRBN E3 ubiquitin ligase, a pivotal element in the ubiquitin-proteasome system. The 4'-ether-alkylC2-amine linker allows the thalidomide moiety to be chemically conjugated to a target protein ligand, forming a functional PROTAC molecule. Upon administration, the bifunctional PROTAC brings the protein of interest into close proximity with the CRBN E3 ligase, promoting polyubiquitination and subsequent proteasomal degradation of the target protein. This selective mechanism bypasses the need for traditional enzyme inhibition, offering a powerful route to modulate previously ‘undruggable’ proteins.

Applications

Thalidomide 4'-ether-alkylC2-amine hydrochloride is widely used in the development of next-generation PROTAC molecules and related targeted protein degradation technologies. Its primary applications include the synthesis of bespoke PROTACs for research in cellular biology, drug discovery, and identification of novel therapeutic targets. The compound serves as a modular E3 ligase recruiting handle, facilitating the creation of libraries of protein degraders aimed at oncology, neurodegenerative diseases, immunology, and beyond. As a result, it is a highly valuable tool for academic labs and pharmaceutical R&D focusing on innovative small molecule therapeutics.

This E3 ligase ligand-linker conjugate is a thalidomide-derived cereblon recruiter designed for modular PROTAC assembly, combining reliable E3 ligase engagement with a short alkyl linker and a terminal amine handle for downstream derivatization. Its compact architecture can support balanced physicochemical properties and efficient synthetic diversification, and the following provides a detailed description of the linker, ligand, and recommended target protein ligand pairing.

Linker: The linker is a short C2 ether-alkyl segment that provides a relatively compact spacer between the cereblon-binding thalidomide core and the terminal coupling handle. This motif offers moderate flexibility with limited conformational reach, while the ether unit can improve polarity and synthetic accessibility. The linker is generally non-cleavable under standard bioconjugation and PROTAC synthesis conditions.

Ligand: The ligand is a thalidomide-based cereblon ligand belonging to the immunomodulatory imide class commonly used for CRBN recruitment in targeted protein degradation studies. Its glutarimide-containing framework is essential for cereblon recognition, while substitution at the 4'-position enables linker installation without fully disrupting the core E3 ligase-binding pharmacophore. This scaffold is widely used because of its established compatibility with PROTAC design.

Reactive Site: The terminal primary amine, supplied here as the hydrochloride salt, serves as the principal reactive site for conjugation to a target protein ligand or an advanced intermediate. After basification or in situ neutralization, this amine is well suited for amide bond formation with carboxylic acid-containing warheads, as well as urea or carbamate-forming transformations with appropriately activated electrophiles. Reductive amination may also be considered when aldehyde-bearing partners are available.

Recommended Target Protein Ligand: This conjugate is particularly compatible with target protein ligands bearing a carboxylic acid or suitably derivatized carbonyl precursor, enabling efficient attachment through the terminal amine. Small-molecule warheads for kinases, bromodomains, or other intracellular protein classes are often suitable when they tolerate installation of a short linker without major loss of affinity. The short C2 spacer may be advantageous when a more compact degrader architecture is desired, especially during early structure-activity relationship studies aimed at optimizing ternary complex formation, permeability, and degradation efficiency.